论文部分内容阅读
目的:观察研究血必净联合常规西药治疗严重脓毒血症的临床疗效。方法:选取2014年1月至2015年5月我科室收诊疗的诊断为严重脓毒血症的患者80例,按随机数字表法分为实验组及对照组各40例,对照组患者给予单独应用常规西药仙力素抗菌治疗,实验组在对照组常规西药治疗基础上加用血必净治疗,记录并分析治疗后两组患者血清Ca2+及APACHEII评分、利钠肽原(NT-pro BNP)和降钙素原(PCT)变化状况。结果:实验组患者治疗后APACHEII为(13.79±2.36),均明显优于对照组(17.42±3.52);实验组治疗后血清Ca2+、N末端B型利钠肽原(NT-pro BNP)和降钙素原(PCT)分别为(2.15±0.12mmol/L、1031±97.5ng/L、7.53±2.04ug/L),均明显优于对照组(1.68±0.23mmol/L、1792±246.1ng/L、14.02±3.57ug/L)。3实验组患者治疗后白细胞计数和中性粒细胞比例分别为(13.76±1.12×109/L、73.92±1.13%),均明显低于对照组(17.11±1.38×109/L、77.64±1.54%)。4实验组患者恢复情况明显优于对照组。结论:血必净联合常规西药治疗严重脓毒血症疗效确切,与常规治疗相比无明显不良反应。
Objective: To observe the clinical efficacy of Xuebijing combined with conventional western medicine in the treatment of severe sepsis. Methods: From January 2014 to May 2015, 80 cases diagnosed as severe sepsis in our department were divided into experimental group and control group according to the random number table method, 40 cases in each group. Patients in the control group were given single The experimental group was treated with Xuebijing in the control group on the basis of conventional western medicine. The serum Ca2 + and APACHEII scores, NT-pro BNP, And procalcitonin (PCT) changes. Results: After treatment, APACHEII in experimental group was (13.79 ± 2.36), which were significantly better than those in control group (17.42 ± 3.52). Serum Ca2 +, NT-pro BNP, (2.15 ± 0.12mmol / L, 1031 ± 97.5ng / L, 7.53 ± 2.04ug / L) were significantly higher than those in the control group (1.68 ± 0.23mmol / L, 1792 ± 246.1ng / L, 14.02 ± 3.57 ug / L). The number of leukocyte and neutrophil in experimental group were (13.76 ± 1.12 × 109 / L, 73.92 ± 1.13%), which were significantly lower than those in control group (17.11 ± 1.38 × 109 / L, 77.64 ± 1.54% ). 4 experimental group was significantly better than the control group recovery. Conclusion: Xuebijing combined with conventional western medicine is effective in treating severe sepsis and has no obvious adverse reactions compared with conventional treatment.